PRECISION MEDICINE DATA PLATFORM
YOUR PARTNER IN MOLECULAR AND REAL-WORLD EVIDENCE DATA FROM PATIENTS
Our approach is based on transformative concept that leverages molecular and clinical RWE data and machine learning/AI and allows us to de-risk upfront theranostic development
Asylia Diagnostics is focusing on the field of immunotherapies. We collect molecular and real-world evidence data from patients treated with investigational drugs in clinical trials and patients treated by the standard of care therapies. We’re building diverse datasets to unlock scientific discoveries as well as improve diagnostic and treatment outcomes
WE DO IT
Our technology allows us to identify non-responders to SoC, dissect patient strata, find relevant biomarkers, and novel targets so we can feed our early pipeline of precision medicine solutions for patients.
AND REAL-WORLD EVIDENCE DATA
We collect molecular and real-world evidence data from patients treated with investigational drugs in clinical trials and patients treated by the standard of care therapies.
TRANSFORM HETEROGENEOUS PATIENT POPULATION INTO SUBGROUPS
Discover well-defined subgroups that share common molecular and immuno-pathophysiology profiles using our proprietary ML-powered platform AsyliaAI™. By doing this we are able to identify highly specific biomarkers and novel drug targets.
DEVELOP PATIENT STRATIFICATION
AND INDICATION EXPANSION STRATEGIES
Use discovered endotypes, biomarkers, and drug targets to develop patient stratification, enrichment, and indication expansion strategies, early hits/leads for the therapeutic pipeline, and complex theranostic products together with our biopharma and IVD partners.
SCALABLE AND PROVEN TECHNOLOGY PLATFORM FOR
The first clinically validated product of Asylia is a molecular test for metastatic melanoma patients treated with immune checkpoint inhibitors (PD1/PD-L1) that allows for predicting the likelihood of adverse events post-treatment and patient response to therapy. This is the first-in-class tool for metastatic melanoma PD-1/L1 patient stratification that should enable treating oncologists with a more informed decision about mono or combo therapy options for stage III of melanoma.
Identify commercial opportunities for indication expansion, novel targets, patient enrichment and stratification, that strengthen the clinical and commercial value proposition and enable precision medicine-driven theranostic development
We have two filed PCTs with positive feedback on novelty and inventiveness and broad claims approved by the EPO and the IP strategy centered on building a battery of biomarkers and composition of matter patents targeting theranostics use cases.
PILOT WITH PHARMA
CO-DEVELOPMENT WITH IVD PARTNERS
CLINICAL TRIALS IN LEADING EUROPEAN HOSPITALS